Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
ONAPGO - official renal prescribing summary
Product / population
ONAPGO 98 mg/20 mL (4.9 mg/mL) solution for continuous subcutaneous infusion in adults with advanced Parkinson disease; not an intermittent apomorphine product. Selected renal sections, not a complete pump prescription.
Renal method
Mild/moderate renal impairment as named in the source; no numerical renal-function cutoff is provided in the selected dosing subsection.
Source revision
Prescribing information revised May 2026; IFU separately revised June 2026.
Retrieved
2026-09-09
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
ONAPGO: initial extra dose differs from continuous and later doses
The May 2026 official renal instruction specifically limits the initial extra dose. The older RX rendering supplies PK information without that usable prescribing subsection.
What to reconcile: Use the complete official product instructions; do not lower every dose automatically or substitute intermittent apomorphine.
DailyMed / MDD US Operations, LLC · ONAPGO 98 mg/20 mL (4.9 mg/mL) solution for continuous subcutaneous infusion in adults with advanced Parkinson disease; not an intermittent apomorphine product. Selected renal sections, not a complete pump prescription.
Renal method: Mild/moderate renal impairment as named in the source; no numerical renal-function cutoff is provided in the selected dosing subsection. Source date: Prescribing information revised May 2026; IFU separately revised June 2026. Retrieved: 2026-09-09
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For mild or moderate renal impairment, the initial extra dose is 0.5-1 mg and must not exceed 1 mg. This renal restriction applies to the initial extra dose: no renal adjustment is needed for the continuous dose, maximum recommended daily dose, or subsequent extra doses. Severe impairment has not been studied. ONAPGO is not substitutable for intermittent apomorphine products. Apply the complete pump training, titration, total-dose, adverse-effect and interaction safeguards; this is not a stand-alone infusion order.
RDM49-official-apomorphine-onapgo-979593b62a-C1 · Source locator: Sections 2.3, 2.5 and 8.6, lines 353-393 and 584-586.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.